BIOMARIN PHARMACEUTICAL INC — Director's Dealing 2013

May 14, 2013

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK: 0001048477
Period of Report: 2013-05-10

Reporting Person: BIENAIME JEAN JACQUES (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2013-05-10	Common Stock	S	800	$67.4810	Disposed	111038	Direct
2013-05-12	Common Stock	F	8873	$67.68	Disposed	102165	Direct
2013-05-13	Common Stock	S	5000	$68.12	Disposed	97165	Direct
2013-05-13	Common Stock	G	7064	—	Disposed	90101	Direct
2013-05-13	Common Stock	G	7064	—	Acquired	20609	Indirect
2013-05-13	Common Stock	S	2000	$69.56	Disposed	88101	Direct
2013-05-13	Common Stock	M	3000	$12.99	Acquired	23609	Indirect
2013-05-13	Common Stock	M	5000	$12.99	Acquired	28609	Indirect
2013-05-13	Common Stock	S	3000	$69.1103	Disposed	25609	Indirect
2013-05-13	Common Stock	S	5000	$69.1130	Disposed	20609	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2013-05-13	Stock Option (right to buy Common Stock)	$12.99	M	3000	Disposed	2016-05-10	Common Stock (3000)	Indirect
2013-05-13	Stock Option (right to buy Common Stock)	$12.99	M	5000	Disposed	2016-05-10	Common Stock (5000)	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	10000	Indirect
Common Stock	10000	Indirect
Common Stock	10000	Indirect
Common Stock	10000	Indirect
Common Stock	20000	Indirect

Footnotes

F1: The price in column 4 is weighted average price. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.

F2: On May 13, 203 the reporting person gifted 7,064 shares of Common Stock to his family trust. The reporting person and his spouse act as trustees for the Bienaime Family Trust.

F3: The reporting person and his spouse act as trustees for the Bienaime Family Trust.

F4: Transaction made pursuant to a 10b5-1 plan executed on August 10, 2012.

F5: The price in column 4 is weighted average price. The price actually received ranged from $67.80 to $69.87. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F6: The price in column 4 is weighted average price. The price actually received ranged from $67.80 to $69.82. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F7: The reporting person's spouse is trustee of each child's trust.

F8: Original option grant vests 6/48th on November 11, 2006 and 1/48th on the 11th day of every month thereafter.

F9: Reflects number of stock options outstanding after the transaction from this specific stock option grant.